Ultragenyx Pharmaceutical Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Ultragenyx reported Q3 2026 revenue of $173M (CRYSVITA $109M, DOJOLVI $30M) and reaffirmed full-year 2026 guidance of $730-760M. The company entered definitive agreements in October 2026 to sell two Priority Review Vouchers (PRVs) received from FDA approvals of GENGLYCOS and FAYUVI for combined $413M ($210M for GENGLYCOS PRV sold; $203M for FAYUVI PRV). Net proceeds expected ~$350M. Ultragenyx initiated substantial restructuring: 20% headcount reduction (to ~1,000 employees), wind-down of GTX-102 studies, termination of UX701 (Wilson disease), targeting 2027 R&D expenses <$350M (vs. $508M in 9M 2026) and SG&A <$375M, with ~$25M restructuring charges in Q4 2026. Company reaffirmed GAAP profitability in 2027 and beyond.
Why this rating
PRV sales ($350M net) represent 10% of market cap and extend runway substantially; 50% R&D reduction plus two new gene therapy launches materially reshape cost structure toward profitability. Against $3.4B market cap, this is significant strategic repositioning, not routine.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.